tradingkey.logo

Third Harmonic Bio Inc

THRD

5.380USD

0.000
終値 09/18, 16:00ET15分遅れの株価
241.86M時価総額
損失額直近12ヶ月PER

Third Harmonic Bio Inc

5.380

0.000
詳細情報 Third Harmonic Bio Inc 企業名
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
企業情報
企業コードTHRD
会社名Third Harmonic Bio Inc
上場日Sep 15, 2022
最高経営責任者「CEO」- -
従業員数53
証券種類Ordinary Share
決算期末Sep 15
本社所在地1700 Montgomery Street
都市SAN FRANCISCO
証券取引所NASDAQ Global Market Consolidated
United States of America
郵便番号94111
電話番号12097272457
ウェブサイトhttps://thirdharmonicbio.com/
企業コードTHRD
上場日Sep 15, 2022
最高経営責任者「CEO」- -
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Christopher M. Murphy
Mr. Christopher M. Murphy
Chief Financial and Business Officer and Principal financial officer
Chief Financial and Business Officer and Principal financial officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Aug 16
更新時刻: Sat, Aug 16
株主統計
種類
株主統計
株主統計
比率
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
他の
43.30%
株主統計
株主統計
比率
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
他の
43.30%
種類
株主統計
比率
Venture Capital
23.08%
Investment Advisor
22.74%
Hedge Fund
19.15%
Private Equity
12.81%
Corporation
5.94%
Investment Advisor/Hedge Fund
5.55%
Pension Fund
1.06%
Research Firm
0.95%
Individual Investor
0.28%
他の
8.44%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
211
40.29M
89.28%
-16.85M
2025Q1
212
42.91M
95.09%
-14.37M
2024Q4
195
49.11M
108.99%
-3.57M
2024Q3
188
48.20M
116.40%
-5.90M
2024Q2
179
44.41M
107.54%
-7.00M
2024Q1
168
42.07M
102.65%
-7.97M
2023Q4
157
42.10M
104.28%
-7.14M
2023Q3
134
41.90M
103.75%
-2.52M
2023Q2
124
40.16M
99.46%
-3.19M
2023Q1
118
40.99M
101.62%
+118.50K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Atlas Venture
10.40M
23.05%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
5.78M
12.81%
--
--
Mar 31, 2025
BML Capital Management LLC
3.82M
8.47%
+100.25K
+2.69%
Mar 31, 2025
Nantahala Capital Management, LLC
2.94M
6.51%
+2.44M
+486.57%
Mar 31, 2025
Novartis AG
2.64M
5.86%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
2.51M
5.55%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
2.92%
+6.37K
+0.49%
Mar 31, 2025
The Vanguard Group, Inc.
1.16M
2.57%
+129.61K
+12.58%
Mar 31, 2025
D. E. Shaw & Co., L.P.
573.33K
1.27%
+562.33K
+5112.13%
Mar 31, 2025
Holles Natalie C
1.22M
2.7%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Wed, Aug 6
更新時刻: Wed, Aug 6
銘柄名
比率
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
詳細を見る
iShares Micro-Cap ETF
比率0.03%
ProShares Ultra Nasdaq Biotechnology
比率0.03%
Invesco Nasdaq Biotechnology ETF
比率0.02%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
iShares Russell 2000 Value ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
iShares Biotechnology ETF
比率0.01%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI